Did you take Xeljanz for at least one year? Have you been diagnosed with cancer, blood clots, or a heart problem?
If you answered yes to these questions, you could be eligible for compensation.
Free Consultation to Join the Xeljanz Lawsuit
Xeljanz and Rheumatoid Arthritis
Rheumatoid arthritis is an autoimmune disease characterized by swelling and pain in the joints.
In 2012, the U.S. Food and Drug Administration approved a new drug called Xeljanz (pronounced ZEL-jans) for the treatment of rheumatoid arthritis. The drug, manufactured by Pfizer, works by suppressing the body’s immune system.
It was later approved to treat psoriatic arthritis and colitis.
A 2019 FDA study connected Xeljanz with blood clotting problems, a risk Pfizer did not warn patients about.
The study prompted the FDA to require Pfizer to add a black box warning to Xeljanz and Xeljanz XR labels to alert patients of the increased risk of blood clots and death. The labels were added in July 2019.
You could be eligible for compensation if you took Xeljanz for at least one year and have been diagnosed with the following health conditions:
- Pulmonary embolism
- Deep vein thrombosis
- Blood clots
- Cardiac arrest
- Cardiovascular death
- Congestive heart failure
- Coronary revascularization
- Myocardial infarction
- Ischemic stroke
The lawsuit does not include generic forms of Xeljanz, which is also called tofacitinib.
Never stop taking a medication without first asking your doctor.
Xeljanz® is a registered trademark of Pfizer and is used here only for the purpose of identifying the product in question. Woods and Woods is not affiliated with, sponsored by, or associated with Pfizer or the U.S. FDA.